Philip Berardi

Physician/Associate Professor

Ottawa Hospital Research Institute

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Immunology Immunology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Philip Berardi is an Associate Professor at the Ottawa Hospital Research Institute in Canada. His research primarily focuses on hematology, particularly in the areas of acute leukemia, donor-derived abnormalities in allogeneic hematopoietic cell transplantation, and the implications of genetic mutations in blood disorders. He has contributed significantly to studies on convalescent plasma for COVID-19 patients and innovative treatment regimens for hematologic malignancies.

Articles (8)

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (7)

Mitchell Sabloff

Head of the Leukemia Program

Ottawa Hospital

CANADA

View details

Michelle Zeller

McMaster University

CANADA

View details

Ljiljana Vasovic

Chief of Clinical Pathology

Westchester Medical Center

UNITED STATES

View details

Andrew W. Shih

CANADA

View details

Jill Fulcher

Assistant Professor, Clinical Hematologist

University of Ottawa Faculty of Medicine

CANADA

View details

David S Allan

University of Ottawa

CANADA

View details

Robert DeSimone

Assistant Professor

Weill Cornell Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Philip Berardi

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus

Systematic Scoping Review of Studies Reporting Unexpected Donor-Derived Abnormalities from Recipients of Allogeneic Hematopoietic Cell Transplantation: A Proposed Framework for Donor Disclosure

Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia

An Unusual Case of Obstructive Shock.

An intron c.149-2632T>A change in RHD is associated with aberrant transcription and very weak D phenotype.

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.

Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case report.

Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to risk-stratify patients for alloimmunisation risk.

Collaborators (7)

Mitchell Sabloff

Michelle Zeller

Ljiljana Vasovic

Andrew W. Shih

Jill Fulcher

David S Allan

Robert DeSimone

Make your next move.